India, Sept. 15 -- Neuland Laboratories is accelerating its peptide manufacturing expansion to meet rising customer demand, with the first of four planned commercial manufacturing modules now operational.
The newly commissioned Module 1 has a total reactor capacity of 7,000 litres, comprising 750 litres of solid-phase peptide synthesis (SPPS) and 6,250 litres of liquid-phase peptide synthesis (LPPS). The facility can support customer programmes ranging from small-scale development to multikilogram production of complete peptide APIs, including complex and long-chain peptides, as well as commercial-scale crude peptide manufacturing.
With the foundational infrastructure for Module 2 already in place, Neuland plans to commence work ahead of ...